Skip to menu Skip to content Skip to footer
Dr John Lee
Dr

John Lee

Email: 
Phone: 
*

Overview

Background

Dr John Lee is the Ross Maclean Senior Research Fellow and a Group Leader at the Queensland Brain Institute (QBI). He holds a joint appointment at UQ’s School of Biomedical Sciences. A mid-career researcher with training in neuroscience, pharmacology, and inflammatory pathways, including the complement system and inflammasomes in motor neuron disease (MND), Huntington’s disease, and Parkinson’s disease.

Dr. Lee completed his PhD at UQ in 2014, before pursuing postdoctoral research in neuroinflammation and neurodegeneration. His translational studies have demonstrated the therapeutic potential of anti-inflammatory compounds to reduce neuronal cell death in animal models, with one candidate advancing to Phase 1B clinical trials. He is also collaborating on novel liquid drug formulations to meet the needs of MND patients who lose the ability to swallow.

Supported by the Ross Maclean Fellowship, which was established in memory of Ross Maclean, who lost his battle with MND in 2005, Dr Lee is working to accelerate drug programs towards the clinic and improve the quality of life for people living with MND.

Availability

Dr John Lee is:
Available for supervision
Media expert

Qualifications

  • Bachelor (Honours) of Science (Advanced), The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Research interests

  • Neuroimmunology in neurodegenerative diseases

    We explore the involvement of innate immune cells in the pathogenesis of MND, HD, and PD to identify potential therapeutic targets. By elucidating the mechanisms underlying neuroinflammation, we aim to develop interventions that halt or slow disease progression.

  • Immunometabolism in neuroinflammation

    Our group investigates the metabolic capacity of innate immune cells within the central nervous system, including neutrophils, macrophages, microglia, and astrocytes. By understanding how alterations in cellular metabolism impact immune function, we aim to uncover new strategies for modulating neuroinflammatory responses.

  • Immune system – Stress response crosstalk

    We explore the intricate relationship between the immune system and the stress response, particularly its implications in neuropsychiatric disorders. By unravelling the molecular mechanisms underlying this crosstalk, we aim to identify new therapeutic targets for conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD).

  • Immunosenescence and Neurological Aging

    Our group investigates the link between the immune system and aging within the context of neurological health. By studying age-related changes in immune function and their impact on brain health, we aim to develop interventions that promote healthy aging and mitigate age-related neurological disorders.

Works

Search Professor John Lee’s works on UQ eSpace

92 works between 2009 and 2025

81 - 92 of 92 works

2016

Conference Publication

A pathogenic role for the C5a receptor, C5aR2, in mouse models of Huntington's and Parkinson's disease

Li, Rui, Lee, John D., Levin, Samantha, Gordon, Richard and Woodruff, Trent M. (2016). A pathogenic role for the C5a receptor, C5aR2, in mouse models of Huntington's and Parkinson's disease. The XXVI International Complement Workshop (ICW), Kanazawa, Japan, 4-8 September 2016. Muenchen, Germany: Elsevier. doi: 10.1016/j.imbio.2016.06.186

A pathogenic role for the C5a receptor, C5aR2, in mouse models of Huntington's and Parkinson's disease

2016

Conference Publication

The complement C5a receptor, C5aR2 contributes to motor deficits in mouse models of Huntington's and Parkinson's disease

Li, R., Levin, S., Lee, J., Gordon, R. and Woodruff, T. (2016). The complement C5a receptor, C5aR2 contributes to motor deficits in mouse models of Huntington's and Parkinson's disease. International Congress of Immunology (ICI), Melbourne, Australia, 21-26 August 2016. Weinheim, Germany: Wiley - VCH. doi: 10.1002/eji.201670200

The complement C5a receptor, C5aR2 contributes to motor deficits in mouse models of Huntington's and Parkinson's disease

2016

Journal Article

Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions

Brennan, Faith H., Lee, John D., Ruitenberg, Marc J. and Woodruff, Trent M. (2016). Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. Seminars in Immunology, 28 (3), 292-308. doi: 10.1016/j.smim.2016.03.015

Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions

2015

Journal Article

Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1<sup>G93A</sup> mouse model of amyotrophic lateral sclerosis

Lee, Jia Y., Lee, John D., Phipps, Simon, Noakes, Peter G. and Woodruff, Trent M. (2015). Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation, 12 (1) 90, 90. doi: 10.1186/s12974-015-0310-z

Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1<sup>G93A</sup> mouse model of amyotrophic lateral sclerosis

2015

Conference Publication

Blood brain barrier impairment alters the pharmacokinetic properties of the complement C5aR1 antagonist PMX205 in mouse models of neurodegeneration

Kumar, Vinod, Lee, John, Noakes, Peter and Woodruff, Trent (2015). Blood brain barrier impairment alters the pharmacokinetic properties of the complement C5aR1 antagonist PMX205 in mouse models of neurodegeneration. 8th International Conference on Complement Therapeutics, Chania, Crete, Greece, 1-6 January 2015.

Blood brain barrier impairment alters the pharmacokinetic properties of the complement C5aR1 antagonist PMX205 in mouse models of neurodegeneration

2014

Other Outputs

The role of complement system in amyotrophic lateral sclerosis

Lee, John (2014). The role of complement system in amyotrophic lateral sclerosis. PhD Thesis, School of Biomedical Sciences, The University of Queensland. doi: 10.14264/uql.2015.156

The role of complement system in amyotrophic lateral sclerosis

2014

Journal Article

Role for terminal complement activation in amyotrophic lateral sclerosis disease progression

Woodruff, Trent M., Lee, John D. and Noakes, Peter G. (2014). Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proceeding of the National Academy of Sciences of the United States of America, 111 (1), E3-E4. doi: 10.1073/pnas.1321248111

Role for terminal complement activation in amyotrophic lateral sclerosis disease progression

2013

Journal Article

Silencing of ghrelin receptor expression inhibits endometrial cancer cell growth in vitro and in vivo

Fung, Jenny N. T., Jeffery, Penny L., Lee, John D., Seim, Inge, Roche, Deborah, Obermair, Andreas, Chopin, Lisa K. and Chen, Chen (2013). Silencing of ghrelin receptor expression inhibits endometrial cancer cell growth in vitro and in vivo. American Journal of Physiology-Endocrinology and Metabolism, 305 (2), E305-E313. doi: 10.1152/ajpendo.00156.2013

Silencing of ghrelin receptor expression inhibits endometrial cancer cell growth in vitro and in vivo

2012

Journal Article

Impairments to the GH-IGF-I axis in hSOD1(G93A) mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis

Steyn, F. J., Ngo, S. T, Lee, J. D., Leong, J. W., Buckley, A. J., Veldhuis, J. D., McCombe, P. A., Chen, C. and Bellingham, M. C. (2012). Impairments to the GH-IGF-I axis in hSOD1(G93A) mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis. Endocrinology, 153 (8), 3735-3746. doi: 10.1210/en.2011-2171

Impairments to the GH-IGF-I axis in hSOD1(G93A) mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis

2012

Book Chapter

Innate immunity in ALS

Lee, John D., Lee, Jia Y., Taylor, Stephen M., Noakes, Peter G. and Woodruff, Trent M. (2012). Innate immunity in ALS. Amyotrophic lateral sclerosis. (pp. 393-412) edited by Martin H. Maurer. Croatia: InTech - Open Access Publisher. doi: 10.5772/30341

Innate immunity in ALS

2010

Conference Publication

Dysregulation of the complement system in neurodegenerative disease

Woodruff, T. M., Lee, J. D., Taylor, S. M. and Noakes, P. G. (2010). Dysregulation of the complement system in neurodegenerative disease. XXIII International Complement Workshop, New York, NY, U.S.A., 1-5 August 2010. Oxford, U.K.: Pergamon Press. doi: 10.1016/j.molimm.2010.05.215

Dysregulation of the complement system in neurodegenerative disease

2009

Journal Article

The C5a anaphylatoxin receptor CD88 is expressed in presynaptic terminals of hippocampal mossy fibres

Crane, James W., Baiquni, Gilang P., Sullivan, Robert K. P., Lee, John D, Sah, Pankaj, Taylor, Stephen M, Noakes, Peter G. and Woodruff, Trent (2009). The C5a anaphylatoxin receptor CD88 is expressed in presynaptic terminals of hippocampal mossy fibres. Journal of Neuroinflammation, 6 (34) 34, 34.1-34.10. doi: 10.1186/1742-2094-6-34

The C5a anaphylatoxin receptor CD88 is expressed in presynaptic terminals of hippocampal mossy fibres

Funding

Current funding

  • 2024 - 2027
    Preclinical development of complement C5a receptor 2 modulators for motor neuron disease
    Cure for MND Foundation - Drug Development Grants
    Open grant
  • 2024 - 2028
    Taming microglial inflammation as a therapeutic avenue to treat MND
    Cure for MND Foundation - Bill Guest Mid-Career Fellowship
    Open grant
  • 2022 - 2026
    Therapeutic Inhibition of Neutrophil Activity as a Disease-Modifying Treatment for Amyotrophic Lateral Sclerosis
    United States Congressionally Directed Medical Research Programs - Amyotrophic Lateral Sclerosis Research Program
    Open grant

Past funding

  • 2024 - 2025
    Examining the efficacy of monepantel in the 6-OHDA model of Parkinson's disease
    PharmAust Limited
    Open grant
  • 2024 - 2025
    Investigating the pharmacological activity of monepantel on autophagy in the NSC-34 motor neuron cell line
    PharmAust Limited
    Open grant
  • 2023 - 2024
    Therapeutic potential of targeting one of the core players of inflammation (Inflammasome) in MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2023 - 2024
    C9orf72 dipeptide-mediated activation of microglia as a therapeutic target for MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2022 - 2024
    Profiling monocytes in MND to assess disease progression and heterogeneity
    Cure for MND Foundation - Impact Grants
    Open grant
  • 2022 - 2023
    The role of glucagon signalling in the progression of MND
    Motor Neurone Disease Research Institute of Australia Inc Innovator Grant
    Open grant
  • 2021 - 2022
    Advancing a clinical drug targeting the complement system to treat COVID-19
    Advance Queensland Industry Research Fellowships
    Open grant
  • 2021 - 2023
    Targeting complement C5a receptor 2 as a disease-modifying treatment for motor neuron disease
    NHMRC Development Grant
    Open grant
  • 2020 - 2024
    Preclinical development of centrally active complement C3a receptor modulators as disease-modifying drugs for motor neuron disease
    Cure for MND Foundation - Drug Development Grants
    Open grant
  • 2020 - 2021
    Investigating the therapeutic inhibition of CXCR2 as a disease modifying treatment for motor neurone disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Investigating the beneficial effects of complement C3aR on immune cell glucose metabolism in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2019 - 2020
    Manipulation of free fatty acid receptors to tame the immune response in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2019
    Therapeutic inhibition of the terminal complement pathway as a disease-modifying treatment for motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2019
    Therapeutic testing of the clinical candidate drug PMX205 in a TDP43-based model of MND and its mechanism
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2018 - 2023
    Discovering new therapies for Motor Neuron Disease
    The University of Queensland in America, Inc
    Open grant
  • 2017 - 2018
    Therapeutic inhibition of HMGB1 to slow disease progression in MND
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant
  • 2016 - 2019
    The role of C3aR signalling in slowing down the disease progression of motor neuron disease
    Motor Neurone Disease Research Institute of Australia Inc
    Open grant

Supervision

Availability

Dr John Lee is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Available projects

  • The role of innate immune and inflammatory pathways in neurodegenerative diseases

  • The link between innate immune system and energy metabolism and its contribution to neurodegeneration

Supervision history

Current supervision

Completed supervision

Media

Enquiries

Contact Dr John Lee directly for media enquiries about their areas of expertise.

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au